No Data
Pepsis (301080.SZ): has successfully developed nearly 40 high-quality GMP-grade products.
On November 4, Gelonhui: BPS Pharmaceuticals (301080.SZ) recently conducted specific research on the 'progress of the company's GMP-grade reagents?' The company stated that, based on having a GMP-level quality management system platform, combined with the production specifications of cell therapy drugs, and stricter quality management and pharmaceutical-grade release testing standards, the company has successfully developed nearly 40 high-quality GMP-grade products, including cellular factors, antibodies and beads for cell activation, universal nucleases, and Cas enzymes, suitable for the large-scale production and clinical research of CGT drugs. Of particular note, the company
Bestcom(301080.SZ): With global supply capabilities, it can fulfill over 90% of global orders within 72 hours.
Gelonghui, November 4th | Beipusi (301080.SZ) recently conducted specific research on "the company's advantages in the supply chain?" The company stated that it has the ability to keenly capture market demand, currently covering over 10,000 end customers, and can quickly insight into market demand through close interaction. The company has unique product design capabilities, relying on six major technology platforms such as multiple transmembrane target proteins, next-generation fluorescent site-specific labeling, ensuring that product design is close to drug development needs. The company has strong product manufacturing capabilities, with production bases established in Peking and Suzhou and plans to expand to the sea.
Baipusaies (301080.SZ): has repurchased a total of 0.0234 million shares.
Grandhope reported on November 4th that as of October 31, 2024, the company repurchased a total of 0.0234 million shares through a share repurchase special securities account in a centralized auction trading manner, accounting for 0.0195% of the total share capital. The highest fill price was 44.44 yuan/share, the lowest fill price was 41.82 yuan/share, and the total fill amount was 0.9959 million yuan (excluding trading fees).
Bepsyth: Report for the third quarter of 2024
Pepsis (301080.SZ): The net income in the first three quarters was 83.49 million yuan, a year-on-year decrease of 34.85%.
On October 29th, Bestsees (301080.SZ) announced its third quarter report for 2024, achieving a revenue of 0.463 billion yuan in the first three quarters, a year-on-year increase of 12.34%; the net income attributable to shareholders of the listed company was 83.49 million yuan, a year-on-year decrease of 34.85%; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 83.5395 million yuan, a year-on-year decrease of 32.85%; basic earnings per share was 0.6973 yuan.
The Recent 8.4% Gain Must Have Brightened CEO Yiding Chen's Week, Acrobiosystems Co.,Ltd.'s (SZSE:301080) Most Bullish Insider
No Data
No Data